Genome Medicine | Tags | #pharmacogenomics

Submit a manuscript Register Follow us on

Explore Genome Medicine

Articles

view #pharmacogenomics on BioMed Central

#pharmacogenomics

25 items(s) found

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	All
	1.	Research highlight Drug transporter regulation in tumors by DNA methylation Oliver Zolk, Martin F Fromm Genome Medicine 2012, 4:10 (31 January 2012) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Oliver Zolk and Martin Fromm highlight a recent observation that uptake transporters for anticancer drugs are epigenetically regulated in hepatocellular carcinoma.
	2.	Research highlight Predicting responses to sunitinib using single nucleotide polymorphisms: Progress and recommendations for future trials Ram N Ganapathi, Ronald M Bukowski Genome Medicine 2011, 3:79 (30 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Ganapathi and Bukowski discuss the advances and pitfalls of a recent study of single nucleotide polymorphisms to predict the activity or toxicity of sunitinib for clear cell renal cell carcinoma.
	3.	Meeting report Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing Mia Wadelius, Ana Alfirevic Genome Medicine 2011, 3:78 (28 December 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mia Wadelius and Ana Alfirevic present highlights from the Cold Spring Harbor and the Wellcome Trust 2011 meeting on 'Pharmacogenomics and Personalized Medicine'.
	4.	Research DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma Elke Schaeffeler, Claus Hellerbrand, Anne T Nies, Stefan Winter, Stephan Kruck, Ute Hofmann, Heiko van der Kuip, Ulrich M Zanger, Hermann Koepsell, Matthias Schwab Genome Medicine 2011, 3:82 (23 December 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary First evidence that decreased protein expression of the transporter SLC22A1 in hepatocellular carcinoma correlates with increased methylation of individual CpG sites.
	5.	Review Pharmacogenetics in type 2 diabetes: potential implications for clinical practice Chunmei Huang, Jose C Florez Genome Medicine 2011, 3:76 (29 November 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Chunmei Huang and Jose Florez review recent insights into type 2 diabetes that are emerging from pharmacogenetic and pharmacogenomic studies, and discuss the potential for clinical translation.
	6.	Research highlight Personalized participatory medicine: sharing knowledge and uncertainty David Gurwitz, Jeantine E Lunshof Genome Medicine 2011, 3:69 (27 October 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary David Gurwitz and Jeantine Lunshof highlight recent research in Genome Medicine exploring the role of patients and doctors in personalizing breast cancer treatment on the basis of genotype information.
	7.	Research Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment Wendy Lorizio, Hope Rugo, Mary S Beattie, Simone Tchu, Teri Melese, Michelle Melisko, Alan HB Wu, H Jeffrey Lawrence, Michele Nikoloff, Elad Ziv Genome Medicine 2011, 3:64 (4 October 2011) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The choice of medication for breast cancer patients was changed after CYP2D6 genotyping, demonstrating for the first time that pharmacogenetics can shape clinical treatment decisions.
	8.	Research Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort Katherine R Smith, Vijayaprakash Suppiah, Kate O'Connor, Thomas Berg, Martin Weltman, Maria Abate, Ulrich Spengler, Margaret Bassendine, Gail Matthews, William L Irving, Elizabeth Powell, Stephen Riordan, Golo Ahlenstiel, Graeme J Stewart, Melanie Bahlo, Jacob George, David R Booth, Genome Medicine 2011, 3:57 (31 August 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Novel variants in the IL28B gene region, which predict lack of response to conventional treatment of hepatitis C virus, are identified through massively parallel sequencing using pooled DNA.
	9.	Review Genetics and genomics of radiotherapy toxicity: towards prediction Catharine M West, Gillian C Barnett Genome Medicine 2011, 3:52 (23 August 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Catharine West and Gillian Barnett review the latest advances in radiotherapy and the recent genome-wide studies that have identified genetic variants linked to radiotoxicity.
	10.	Review Biomarkers in solid organ transplantation: establishing personalized transplantation medicine Silke Roedder, Matthew Vitalone, Purvesh Khatri, Minnie M Sarwal Genome Medicine 2011, 3:37 (8 June 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Minnie Sarwal and colleagues review the rocky road to regulatory approval in the search for biomarkers for organ transplants that will help predict the chances of success and increase graft survival.
	11.	Research highlight Personalizing carbamazepine therapy Taisei Mushiroda, Yusuke Nakamura Genome Medicine 2011, 3:28 (30 May 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Mushiroda and Nakamura highlight recent studies that could facilitate the development of genetic tests to predict individuals at risk for serious adverse reactions to carbamazepine.
	12.	Review Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances Enrico Derenzini, Anas Younes Genome Medicine 2011, 3:26 (28 April 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Derenzini and Younes review advances in genomic technologies that have allowed the identification of new biomarkers for predicting disease and treatment outcome in classical Hodgkin lymphoma.
	13.	Review Inherited destiny? Genetics and gestational diabetes mellitus Richard M Watanabe Genome Medicine 2011, 3:18 (25 March 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Richard Watanabe reviews our understanding of the genetic basis of gestational diabetes mellitus and discusses whether this may be furthered by the recent dramatic gains in our knowledge of the genomics of other types of diabetes.
	14.	Review Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics John E Tavis, Maureen J Donlin, Rajeev Aurora, Xiaofeng Fan, Adrian M Di Bisceglie Genome Medicine 2011, 3:8 (8 February 2011) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Antiviral therapy for hepatitis C will change dramatically in the near future as our understanding of how host and viral genetic variation affect the treatment outcome improves.
	15.	Review The pharmacogenetics of imatinib Stéphanie Dulucq, Maja Krajinovic Genome Med 2010, 2:85 (30 November 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The response to imanitib, a tyrosine kinase inhibitor used to treat various cancers, depends on genetic variation in several enzymes and transporters.
	16.	Meeting report Pharmacogenetics and pharmacogenomics: practical applications in routine medical practice Anke-Hilse Maitland-van der Zee, Ana Alfirevic Genome Medicine 2010, 2:69 (21 September 2010) Abstract \| Full text \| PDF \| PubMed
	17.	Review Pharmacogenomic considerations in the opioid management of pain Paul J Jannetto, Nancy C Bratanow Genome Medicine 2010, 2:66 (15 September 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Pharmacogenomics can lead to more efficient opioid selection to minimize adverse drug reactions and improve patient outcome.
	18.	Commentary The public health utility of genome-wide association study results for smoking behavior Helena Furberg, Jamie Ostroff, Caryn Lerman, Patrick F Sullivan Genome Medicine 2010, 2:26 (27 April 2010) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary To reduce the burden of smoking on society, multidiciplinary research is needed to help translate genome-wide association studies for smoking behavior to the clinic.
	19.	Meeting report Pharmacogenomics and personalized medicine: lost in translation? Jean-Sébastien Hulot Genome Medicine 2010, 2:13 (22 February 2010) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary A report on the Joint Cold Spring Harbor/Wellcome Trust Conference 'Pharmacogenomics & Personalized Medicine', Hinxton, UK, 12-15 September 2009.
	20.	Review Pharmacogenomic insights into treatment and management of statin-induced myopathy Bas JM Peters, Olaf H Klungel, Frank L Visseren, Anthonius de Boer, Anke-Hilse Maitland-van der Zee Genome Medicine 2009, 1:120 (29 December 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genotyping in patients suffering from statin-induced myopathy may help to personalize the choice of statin by reducing the chance of developing this rare but serious side-effect.
	21.	Review Chronic obstructive pulmonary disease: towards pharmacogenetics Alice M Wood, See Ling Tan, Robert A Stockley Genome Medicine 2009, 1:112 (30 November 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Knowledge of the pathophysiology and genetic risk factors for chronic obstructive pulmonary disease may help identify individuals who will respond differently to treatments.
	22.	Research Networking of differentially expressed genes in human cancer cells resistant to methotrexate Elisabet Selga, Carlota Oleaga, Sara Ramírez, M Cristina de Almagro, Véronique Noé, Carlos J Ciudad Genome Medicine 2009, 1:83 (4 September 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary Dikkopf homolog-1, UDP-glucuronosyltransferase 1A and Eukaryotic translation elongation factor 1 alpha 1 play key roles in the development of resistance to methotrexate and offer novel therapeutic targets for chemosensitization to cancer therapy.
	23.	Commentary Genome-wide association studies in pharmacogenomics: untapped potential for translation Idris Guessous, Marta Gwinn, Muin J Khoury Genome Med 2009, 1:46 (28 April 2009) Abstract \| Full text \| PDF \| PubMed \| Cited on BioMed Central \| Editor’s summary The integration of genome-wide association studies within the design of pharmacogenomics trials is currently underexploited but holds promise for accelerating the transfer of gene discoveries into clinical practice.
	24.	Review Systems pharmacology and genome medicine: a future perspective Aislyn D Wist, Seth I Berger, Ravi Iyengar Genome Med 2009, 1:11 (22 January 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genome medicine forms the base on which systems pharmacology can develop, and the interface of the two fields will enable drug discovery for individualized medicine.
	25.	Review Pharmacogenomics of anticoagulants: steps toward personal dosage Ann K Daly Genome Medicine 2009, 1:10 (21 January 2009) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary Genetic variation is increasingly recognized to be an important determinant of warfarin and other coumarin anticoagulant dose requirements for an effective and safe response.